|
|
|
|
|
Analysis on the differences in patients with acute exacerbation of chronic heart failure between emergency department and cardiology department |
|
|
Abstract Objective To analyze the differences in patients with acute exacerbation of chronic heart failure between emergency department and cardiology department. Methods Patients with acute exacerbation of chronic heart failure whose left ventricular ejection fraction (LVEF) was less than 40% were enrolled from July 2014 to December 2016 in the emergency department and cardiology department of Peking University People′s Hospital. Data for basic information, past medical history, admission conditions, accessory examinations, treatments during hospitalization, nosocomial outcomes and discharge medications were collected. According to the in patient departments, they were divided into the emergency department treatment group and the cardiology department treatment group. All analyses were performed with SPSS 21.0 statistical software package. Results In total, 203 patients were enrolled and 12 patients (9.9%) died. 53 patients (26.1%) were hospitalized in the emergency department and 150 patients (73.9%) were hospitalized in the cardiology department. Compared to the cardiology department treatment group, age, proportions with coronary heart disease and diabetes history, proportion of heart function classification Ⅳ, systolic blood pressure, heart rate, white blood cell, C reactive protein, aspartate aminotransferase, blood urea nitrogen, LVEF, the first dose and the maximum daily dose of furosemide, proportions of nitrates and non-invasive mechanical ventilation and mortality were higher in the emergency department, but hemoglobin, hematocrit, serum sodium and estimated glomerular filtration rate were lower (P<0.05). Excluding the deaths, the proportions of sequential oral diuretics, inotropes, nitrates, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, β receptor blocker and mineralocorticoid receptor antagonist at discharge were lower in the emergency department (P<0.05). Conclusion Patients with acute exacerbation of chronic heart failure in the emergency department have shorter hospital duration, but they have more risk factors, worse conditions, higher mortality, and the proportions of sequential oral drugs are lower at discharge.
|
|
|
|
|
[1]中华医学会心血管病学分会,中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2014[J]. 中国心血管病杂志, 2014, 42(2):98-122.
[2]Maggioni AP, Dahlstrm U, Filippatos G, et al. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot)[J]. Eur J Heart Fail, 2013, 15(7):808-817.
[3]Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure[J]. Nat Rev Cardiol, 2011, 8(1):30-41.
[4]Metra M, Zaca V, Parati G, et al. Cardiovascular and noncardiovascular comorbidities in patients with chronic heart failure[J]. J Cardiovasc Med (Hagerstown), 2011, 12(2):76-84.
[5]He J, Ogden LG, Bazzano LA, et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study[J]. Arch Intern Med, 2001, 161(7):996-1002.
[6]Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes[J]. Circulation, 2001, 103(22):2668-2673.
[7]Parissis JT, Rafouli-Stergiou P, Mebazaa A, et al. Acute heart failure in patients with diabetes mellitus: clinical characteristics and predictors of in-hospital mortality[J]. Int J Cardiol, 2012, 157(1):108-113.
[8]Stiell IG, Clement CM, Brison RJ, et al. A risk scoring system to identify emergency department patients with heart failure at high risk for serious adverse events[J]. Acad Emerg Med, 2013, 20(1):17-26.
[9]Lee DS,Stitt A, Austin PC, et al. Prediction of heart failure mortality in emergent care: a cohort study[J]. Ann Intern Med, 2012, 156(11):767-775.
[10]Peterson PN, Rumsfeld JS, Liang L, et al. A validated risk score for in-hospital mortality in patients with heart failure from the American Heart Association get with the guidelines program[J]. Circ Cardiovasc Qual Outcomes, 2010, 3(1):25-32.
[11]Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure[J]. Circulation, 2006, 113(5):671-678.
[12]Smith GL, Lichtman JH, Bracken MB, et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis[J]. J Am Coll Cardiol, 2006, 47(10):1987-1996.
[13]Engstrom G, Melander O, Hedblad B. Leukocyte Count and Incidence of Hospitalizations Due to Heart Failure[J]. Circ Heart Fail, 2009, 2(3):217-222.
[14]Anand IS. C-Reactive Protein in Heart Failure: Prognostic Value and the Effect of Valsartan[J]. Circulation, 2005, 112(10):1428-1434.
[15]Verma S, Li SH, Badiwala MV, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein[J]. Circulation, 2002, 105(16):1890-1896.
[16]Salisbury AC, Kosiborod M. Outcomes associated with anemia in patients with heart failure[J]. Heart Fail Clin, 2010, 6(3):359-372.
[17]Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC).[J]. Eur J Heart Fail, 2016, 18(8):891-975.
[18]SOLVD Investigators, Yusuf S, Pitt B, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators[J]. N Engl J Med, 1991, 325(5):293-302.
[19]Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials[J]. JAMA, 1995, 273(18):1450-1456.
[20]Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)[J]. New Engl J Med, 1987, 316(23):1429-1435.
[21]No authors listed. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)[J]. Lancet, 1999, 353(9169):2001-2007.
[22]No authors listed. The Cardiac Insufficiency Bisoprolol Study Ⅱ(CIBIS-Ⅱ): a randomised trial[J]. Lancet, 1999, 353(9146):9-13.
[23]Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study[J]. Circulation, 2002, 106(17):2194-2199.
[24]Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)[J]. Eur Heart J, 2005, 26(3):215-225.
[25]Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure〖JP〗. Randomized Aldactone Evaluation Study Investigators[J]. N Engl J Med, 1999, 341(10):709-717.
[26]Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms[J]. N Engl J Med, 2011, 364(1):11-21. |
|
|
|